Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Fig. 3

Proportion of responders (total inflammatory joint disease population) at a 3 months and b 6 months, stratified by certolizumab level (mg/L) at 3 months. Response in axial spondyloarthritis was defined by Clinically important improvement the Ankylosing Spondylitis Disease Activity Score, in rheumatoid arthritis as European League Against Rheumatism good/moderate response, and in psoriatic arthritis as improvement of ≥ 0.6 in 28-joint Disease Activity Score

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us